Literature DB >> 16626891

Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique.

Peter Acher1, Rick Popert, Janette Nichol, Louis Potters, Stephen Morris, Ronald Beaney.   

Abstract

PURPOSE: A permanent prostate brachytherapy (PPB) program utilizing intraoperative inverse-planned dynamic dose-feedback was initiated without prior firsthand experience of alternative techniques. The purpose of this study is to assess the dosimetric learning curve associated with this approach. METHODS AND MATERIALS: A total of 77 patients underwent PPB implants as monotherapy for localized prostate cancer to a prescription dose of 145 Gy with loose 125I seeds between December 2003 and June 2004. Intraoperative and postoperative dosimetric values, total implanted radioactivity, and operating room (OR) times were compared by sequential case number for all cases.
RESULTS: The median intraoperative dosimetric values were: D90 (the minimum dose to 90% of the prostate) = 170 Gy (range, 135-203 Gy), V100 (the volume of the prostate that receives 100% of the prescription dose) = 96% (range, 86-100), V150 = 66% (range, 34-86). Median postoperative dosimetric values were as follows: D90 = 168 Gy (range, 132-197 Gy), V100 = 95% (range, 86-99), V150 = 74% (range, 51-84). Median implanted activity was 0.79 mCi per cubic centimeter of prostate (range, 0.541-1.13). There was no significant correlation by case number on any postoperative dosimetric parameter studied. Door-to-door OR time was reduced from median 138 to 97.5 min per case at the end of the series with a correlation coefficient of -0.76 for the initial 28 cases.
CONCLUSION: Satisfactory dosimetric parameters can be achieved from the outset without a learning curve effect in an appropriately trained environment. The learning curve for dynamic dose-feedback PPB in a clinic naïve to other techniques is apparent in terms of OR time.

Entities:  

Mesh:

Year:  2006        PMID: 16626891     DOI: 10.1016/j.ijrobp.2006.01.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Robotic assistance for ultrasound-guided prostate brachytherapy.

Authors:  Gabor Fichtinger; Jonathan P Fiene; Christopher W Kennedy; Gernot Kronreif; Iulian Iordachita; Danny Y Song; Everette C Burdette; Peter Kazanzides
Journal:  Med Image Anal       Date:  2008-06-18       Impact factor: 8.545

2.  Utilizing different methods for visualizing susceptibility from a single multi-gradient echo dataset.

Authors:  Gopal Varma; Steen Fjord Pedersen; Matthias Taupitz; Rene Michael Botnar; Hannes Dahnke; Stephen Frederick Keevil; Tobias Schaeffter
Journal:  MAGMA       Date:  2009-07-31       Impact factor: 2.310

Review 3.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

4.  Simulation as More Than a Treatment-Planning Tool: A Systematic Review of the Literature on Radiation Oncology Simulation-Based Medical Education.

Authors:  Michael K Rooney; Fan Zhu; Erin F Gillespie; Jillian R Gunther; Ryan P McKillip; Matthew Lineberry; Ara Tekian; Daniel W Golden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-06       Impact factor: 7.038

5.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

6.  A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.

Authors:  Mark E Hwang; Paul J Black; Carl D Elliston; Brian A Wolthuis; Deborah R Smith; Cheng-Chia Wu; Sven Wenske; Israel Deutsch
Journal:  Radiat Oncol       Date:  2018-10-01       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.